{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:11:14Z","timestamp":1790158274540,"version":"4.1.0"},"reference-count":46,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"BeOne Medicines USA, Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"DOI":"10.1080\/14737140.2026.2722166","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:53:34Z","timestamp":1790002414000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Prospective patient preference study for chronic lymphocytic leukemia (CLL) treatment attributes impacting patient shared decision-making"],"prefix":"10.1080","author":[{"given":"Sikander","family":"Ailawadhi","sequence":"first","affiliation":[{"name":"Mayo Clinic","place":["Jacksonville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha","family":"Challagulla","sequence":"additional","affiliation":[{"name":"BeOne Medicines USA","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Meng","sequence":"additional","affiliation":[{"name":"Analysis Group","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todor I.","family":"Totev","sequence":"additional","affiliation":[{"name":"Analysis Group","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Pilon","sequence":"additional","affiliation":[{"name":"Analysis Group","place":["Montreal, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Diaz","sequence":"additional","affiliation":[{"name":"Analysis Group","place":["Montreal, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Chen","sequence":"additional","affiliation":[{"name":"Analysis Group","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri","family":"Yang","sequence":"additional","affiliation":[{"name":"BeOne Medicines USA","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0239-8"},{"key":"e_1_3_5_3_1","unstructured":"Surveillance Epidemiology and End Results (SEER) Program. Cancer stat facts: NHL \u2014 chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) [Internet]. National Cancer Institute; 2024 [cited 2024 Sep 13]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/cllsll.html"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051583"},{"key":"e_1_3_5_5_1","unstructured":"Ratner E. Decision making about treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL) [Internet]. CLL Society; 2023 Apr 26 [cited 2025 Aug 8]. Available from: https:\/\/cllsociety.org\/2023\/04\/decision-making-about-treatment-of-cll-sll\/"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S289139"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017007294"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2348440"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000771"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2024.2366534"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4020-5753-3"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7436.360"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.12.004"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.2223"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-024-01431-6"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37648-w"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788133"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30909-9"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200006"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"e_1_3_5_21_1","volume-title":"VENCLEXTA (venetoclax) prescribing information","year":"2024","unstructured":"VENCLEXTA (venetoclax) prescribing information. North Chicago (IL): AbbVie Inc.; 2024 Jul."},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00293-5"},{"key":"e_1_3_5_24_1","volume-title":"BRUKINSA (zanubrutinib) prescribing information","year":"2024","unstructured":"BRUKINSA (zanubrutinib) prescribing information. San Mateo (CA): BeiGene USA Inc; 2024 Jun."},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000801"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01485-x"},{"key":"e_1_3_5_28_1","volume-title":"CALQUENCE (acalabrutinib) prescribing information","year":"2024","unstructured":"CALQUENCE (acalabrutinib) prescribing information. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2024 Jun."},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006434"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638"},{"key":"e_1_3_5_31_1","volume-title":"IMBRUVICA (ibrutinib) prescribing information","year":"2024","unstructured":"IMBRUVICA (ibrutinib) prescribing information. South San Francisco (CA): Pharmacyclics LLC; 2024 May."},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.4337\/9781800375635.00013"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0734-2"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-015-0118-z"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826080-00004"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2026.2617270"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0904569"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2013.07.001"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2310144"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000969468.03128.c0"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S106629"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.11.006"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.259432"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.2903"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.107326"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2008.01.013"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.34172\/jcs.33287"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2026.2722166","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14737140.2026.2722166","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2026.2722166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:39:39Z","timestamp":1790156379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2026.2722166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":46,"alternative-id":["10.1080\/14737140.2026.2722166"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2026.2722166","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}